2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Manzi Giovanna, Badagliacca Roberto, D'Alto Michele, Ghio Stefano, Palazzini Massimiliano, Romeo Emanuele, Scelsi Laura, Airò Edoardo, Argiento Paola, Baldi Fabiana, Bauleo Carolina, Bonsante Edoardo, Carignola Renato, Carmina Maria Gabriella, Cannillo Margherita, Casu Gavino, Confalonieri Marco, Corda Marco, Correale Michele, D'Angelo Luciana, De Michele Lucrezia, Fortunato Fabrizio, Galié Nazzareno, Galgano Giuseppe, Garascia Andrea, Giuliani Livio, Marra Walter Grosso, Madonna Rosalinda, Mercurio Valentina, Monti Simonetta, Mulé Massimiliano, Paciocco Giuseppe, Papa Silvia, Pezzuto Beatrice, Prati Daniele, Raineri Claudia, Romaniello Antonella, Renon Francesca, Stolfo Davide, Vatrano Marco, Vitulo Patrizio, Manes Alessandra, Vizza Carmine Dario
Аннотация
METHODS: A consensus document containing 10 statements, mainly focused on the use of parenteral prostanoids, was developed by eight experts in PAH during in-person and web-based meetings. Forty-six physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement.
RESULTS: Forty physicians participated to the survey. There was strong agreement that age and comorbidities significantly influence the choice of PAH-targeted therapies. Agreement was also reached on the use of parenteral prostanoids in the following clinical scenarios: a) treatment-naive patients at high risk; b) newly diagnosed patients classified as intermediate-risk, with severe right ventricular dysfunction assessed invasively and c) prevalent high-risk patients, as defined by the 4-strata risk score. The use of parenteral prostanoids in selected newly diagnosed intermediate-risk patients with severe right ventricular dysfunction assessed by imaging achieved a mild agreement. Three statements did not meet the predefined threshold for consensus.
CONCLUSIONS: These consensus statements are intended to support physicians in starting parenteral prostanoids, minimizing delays that could negatively affect patient prognosis.